Ochs H
No ORCID on file
· 9 papers in corpus
· active 1986-1995
Study types
- article 9
Condition tags
- endometriosis 9
- dysmenorrhea 2
- chronic_pelvic_pain 1
- mesh:D004716 1
- dyspareunia 1
Top journals
Frequent coauthors
article
1995
To compare treatment efficacy and safety parameters a total of 55 premenopausal women with histologically proven endometriosis (stage II-IV) were randomized to receive the LHRH-analogue depot triptorelin (n = 30) or the steroid danazol (n =…
article
1994
A phase III multicentre study was carried out with the GnRH agonist buserelin (Suprecur) at five university institutions (Dept. of Obstetrics and Gynaecology of Essen, Kiel, Tübingen, Münster and Erlangen) to evaluate the effect of Busereli…
article
1993
A panel of monoclonal antibodies specific for macrophage subtypes appearing in early (27E10), down-regulatory (RM3/1) and late (25F9) stages of inflammation had been applied to 20 endometriotic implants of 14 women. Of those patients 9 were…
article
1991
CA 125, CA 19-9, CA 15-3 and CEA were measured in 42 patients with histologically verified endometriosis, who had been treated for six months by the LHRH-analogue buserelin (900 mcg/d intranasally). Before therapy, for all of the markers te…
article
1990
LHRH analogue therapy has proved effective in the treatment of endometriosis. Although in the majority of patients a marked reduction in AFS implant score is observed, in some cases residual endometriotic foci are macroscopically suspected …
article
1989
To investigate the effects of the LH-RH agonist Buserelin [D-Ser (But)6 des-Gly10-LHRH ethylamide] on endometriosis, 64 patients were treated with 900 micrograms/d Buserelin intranasally over 6 months after histological verification of the …
article
1987
Between 1983 and 1986 40 patients were treated for external genital endometriosis with the LHRH agonist buserelin. Ovarian suppression was achieved for a period of six months with a dose of 900 to 1,800 mcg per day. In addition to gynecolog…
article
1986
article
1986